Loungani RS, Rehorn MR, Geurink KR, et al. - Given patients with cardiac amyloidosis (CA) often develop atrial arrhythmias, researchers focused on the safety or efficacy of cardioversion (DCCV) for the treatment of these rhythms in CA. They analyzed 25 patients with CA, including 20 with transthyretin and 5 with light-chain amyloidosis, recruited from Duke University, who had undergone DCCV for atrial arrhythmias. They focused on procedural success, complications, and long-term morbidity and mortality. Successful restoration of sinus rhythm was achieved in 96% of patients who underwent DCCV. Immediate procedural complications (mainly bradycardia and hypotension) were reported in 36% of patients. Recurrence of atrial arrhythmias at one year and death at 3 years was reported in 80% and in 52% of patients, respectively. Findings revealed short-term safety concerns, long-term inefficacy, and poor prognosis related to symptomatic atrial arrhythmias necessitating DCCV in CA.